Diagnostikk og behandling av gynekologisk kreft
- Prosjektnummer
- SFP989-11
- Ansvarlig person
- Anne Ørbo
- Institusjon
- Universitetssykehuset Nord-Norge HF
- Prosjektkategori
- Flerårig forskningsprosjekt
- Helsekategori
- Cancer and neoplasms
- Forskningsaktivitet
- 6. Treatment Evaluation
Increased gene expression of the ABCC5 transporter without distinct changes in the expression of PDE5 in human cervical cancer cells during growth.
Anticancer Res 2012 Aug;32(8):3055-61.
PMID: 22843873
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix.
Anticancer Res 2011 Jun;31(6):2319-25.
PMID: 21737658
Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia:
BJOG Article first published online: 28 NOV 2013
Article first published online: 28 NOV 2013
Publikasjonskanal, årstall
. Diagnostics of co-existent carcinoma in high risk endometrial hyperplasia: significance of 4C-rule and EIN for outcome of pred
2011 Virchows Arch 459 (Suppl 1): S1-S329. S29 Oral presentation. 23 European Congress of Pathology, Helsinki 27 August - 1 September 2011
Extranuclear steroid-initiated signaling by
2011 Virchows Arch 459 (Suppl 1): S1-S329. S242, Poster presentation, 23 European Congress of Pathology, Helsinki 27 August - 1 September 2011
Successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system coincides with down-regula
International Gynecologic Cancer Society Praha. 23-26 oct. 2010
Successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system coincides with down-regula
2011 Virchows Arch 459 (Suppl 1): S1-S329. S256, Poster presentation, 23 European Congress of Pathology, Helsinki 27 August - 1 September 2011
. Ny metode for identifisering og klassifisering av forstadier til livmorkreft
Best Practice. 2011; 4: 22- 26
Vascular markers CD31, CD34, actin, VEGFB, and VEGFR2, are prognostic markers for malignant development in benign endo-metrial p
Akseptert OJOG 23122011
Can endometrial hyperplasia be treated with a levonorgestrel impregnated intrauterine device? Trial protocol for a prospective
Submitted BMC Women's health 15122011
Overlege
- Disputert:
- juni 2012
- Hovedveileder:
- Anne Ørbo
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord